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CObjective: To evaluate the cost-effectiveness of different tuberculosis
control strategies in Thailand. Methods: Different tuberculosis control
strategies, which included health-worker, community-member, and
family-member directly observed treatment (DOT) and a mobile phone
“contact-reminder” system, were compared with self-administered
treatment (SAT). Cost-effectiveness analysis was undertaken by using
a decision tree model. Costs (2005 international dollars [I$]) were cal-
culated on the basis of treatment periods and treatment outcomes.
Health outcomes were estimated over the lifetime of smear-positive
pulmonary tuberculosis patients in disability-adjusted life years
(DALYs) averted on the basis of Thai evidence on the efficacy of the
selected strategies. Results: Cost-effectiveness results indicate no
reference for any strategy. The uncertainty ranges surrounding the
ealth benefits were wide, including a sizeable probability that SAT
ould lead to more health gain than DOT strategies. The health gain for
amily-member DOT was 9400 DALYs (95% uncertainty interval 7200
o 25,000), for community-member DOT was 13,000 DALYs (95% uncer- O
e no
opul
al So
doi:10.1016/j.jval.2011.11.006ainty interval21,000 to 37,000), and for health-worker DOT was 7900
ALYs (95% uncertainty interval 50,000 to 43,000). There were cost
avings (from less multi-drug resistant tuberculosis treatment) associ-
ted with family-member DOT (I$9 million [95% uncertainty interval
I$12 million to I$5 million]) because the trial treatment failure rate
as significantly lower than that for SAT. The mobile phone reminder
ystem was not cost-effective, because the mortality rate associated
ith it was much higher than that associated with other treatment
trategies. Conclusions: Because of the large uncertainty intervals
round health gain for DOT strategies, it remains inconclusive whether
OT strategies are more cost-effective than SAT. It is evident, however,
hat family-member DOT is a cost-saving intervention.
eywords: cost-effectiveness, DOT, mobile phone reminder, self-ad-
inistered treatment, Thailand, tuberculosis.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Tuberculosis (TB) remains one of the global leading public health
problems. In 2007, Thailand ranked 18th out of the 22 high-burden
countries globally. Thailand has met one of the global targets that
have been set by the World Health Assembly and the Stop TB
Partnership as well as are within the framework of the Millennium
Development Goals, for 70% detection of new smear-positive
cases but has not yet achieved successful treatment of 85% [1].
Effective cure of TB requires a patient taking medication
without interruption following a strict schedule for at least 6
months, which is difficult for most patients to maintain. Di-
rectly observed treatment (DOT), whereby a trained person ob-
serves patients taking their medications, is widely used to im-
prove adherence to treatment. It is worth noting that DOT and
DOTS (directly observed treatment, short course) are different
terms. DOT is one of the five key components of DOTS, which is
recommended by the World Health Organization (WHO) [2]. The
five key components are 1) government commitment, 2) case
detection by sputum smear microscopy, 3) standardized treat-
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Published by Elsevier Inc.ment regimen with DOT, 4) a regular drug supply, and 5) a stan-
dardized recoding and reporting system. There are three DOT
options commonly used: health worker, community member,
and family member [3,4].
There have been a few cost-effectiveness studies comparing DOT
to self-administered treatment (SAT), but none has been conducted
in Thailand [5,6]. A Cochrane review found no evidence that DOT
shows better cure rates than does SAT [7]; however, a Thai trial [8]
that was included in the review showed that DOT provides modest
additional benefits.
Recently, mobile phones have gained attention in health care. As
mobile technologies improve health systems and the delivery of
health care [9], several researchers have shown evidence that mobile
phones have the potential to improve health outcomes in the devel-
oping world [10]. There have been a few studies of the use of mobile
phone in a TB control program [9,11,12]. To our knowledge, no other
studies have evaluated the cost-effectiveness of the mobile phone
intervention compared with that of SAT. In this article, we evaluated
the cost-effectiveness of five different strategies, including different
DOT options, mobile phone intervention, and SAT.
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Interventions and comparator
We reviewed the TB control strategy literature to identify interven-
tions that would be suitable to implement in Thailand and had evi-
dence of efficacy to support the analyses. The three DOT options are
Fig. 1 – Decision tree of different TB control strategies. CM, c
FM, family member; HIV−, HIV negative; HW, health worker
tuberculosis; S, successful treatment; SAT, self-administeredrecommended methods of supervision by the WHO, depending onthe distance between a patient’s place and a health facility [4], while
mobile phone intervention has become an interesting alternative as
it has become ubiquitous. Five interventions were included in the
cost-effectiveness analysis: health-worker DOT, community-mem-
ber DOT, family-member DOT, mobile phone “contact-reminder”
system, and SAT. We used SAT as the comparator for each DOT
strategy and the mobile phone intervention. A description of each
unity member; D, died; DOT, directly observed treatment;
R-TB, multi-drug resistant tuberculosis; PTB, pulmonary
atment; SS+, sputum smear-positive; T, transferred out.omm
; MDintervention is as follows:
S52 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 5 0 – S 5 5DOT: Patients’ drug intake is supervised daily for 6 months by a
health worker at a health-care facility (health-worker DOT), a
village health volunteer (community-member DOT), or a fam-
ily member (family-member DOT) at the patients’ home.
Mobile phone “contact-reminder”: For 6 months, patients are re-
minded via a mobile phone to take their daily medication by
village health volunteers who have previously completed their
own TB treatment.
SAT: Patients take their daily medication without supervision for 6
months.
For all interventions, patients are followed up twice per month
in the first 2 months and monthly thereafter either at home or in a
health-care facility by health workers.
Tuberculosis model
The cost-effectiveness of the selected TB control strategies was
evaluated in a decision tree model. The model was constructed in
Microsoft Excel with the add-in tool Ersatz (www.epigear.com) for
uncertainty analysis.
The model has three stages of treatment: initial treatment, re-
treatment, and multi-drug resistant TB (MDR-TB) treatment
(Fig. 1). A patient who fails the initial treatment is treated again in
stage two called “re-treatment.” A retreated patient who fails re-
treatment is treated again in stage three called “MDR-TB treat-
ment.” The treatment period varies according to the stage of treat-
ment [13–15]. The initial treatment lasts 6 months, the
retreatment lasts 8 months, and the MDR-TB treatment lasts 18
months. We used standard treatment outcome definitions from
the WHO [1], grouped into four categories: successful treatment
(cured or treatment completed), failed (treatment failure or de-
faulted), transferred out, or died. For each intervention, a patient
can follow one of nine possible pathways: success1, success2, suc-
cess3, transfer1, transfer2, transfer3, die1, die2, or die3 (Fig. 1).
Table 1 – Effects of interventions.
Intervention Success rate (95% CI) Failure rate (9
DOT by an HW 0.87 (0.70–0.97) 0.04 (0.00–0
DOT by a CM 0.79 (0.64–0.91) 0.15 (0.05–0
DOT by an FM 0.84 (0.80–0.88) 0.08 (0.05–0
Mobile phone 0.82 (0.72–0.90) 0.01 (0.00–0
SAT 0.76 (0.72–0.80) 0.14 (0.11–0
CI, confidence interval; CM, community member; DOT, directly obser
istered treatment.
Table 2 – Uncertainty distributions around parameters for
Parameter Value
Pulmonary TB disability weight 0.29, 95% CI 0.181–0.406
Numbers of outcomes for initial
treatment
N  24, n1  21, n2  1, n3 
N  34, n1  27, n2  5, n3 
N  352, n1  297, n2  27, n
N  71, n1  58, n2  1, n3 
N  422, n1  320, n2  61, n
Numbers of outcomes in untreated
group
N  126, n1  35, n2  53, n
Numbers of outcomes for retreatment N  967, n1  612, n2  216,
Numbers of outcomes for MDR-TB
treatment
N  13, n1  5, n2  0, n3 
CI, confidence interval; DOT, directly observed treatment; MDR-TB, m
treated; n2, number of failed treatments; n3, number of deaths; n4,
self-administered treatment; TB, tuberculosis.Probabilities of treatment outcomes from the initial treatment
are different by interventions and comparator. Treatment out-
comes from DOT interventions and SAT were derived from a Thai
randomized controlled trial [8]. Treatment outcomes from the mo-
bile phone intervention were derived from a mobile phone moni-
toring care study [12]. Table 1 shows treatment outcomes of each
intervention. We assumed that each intervention had the same
set of probabilities of treatment outcomes for retreatment and
MDR-TB treatment. These probabilities were derived from the Na-
tional TB Program [16] and an MDR-TB study conducted in Thai-
land [17], respectively.
We focused our study on treated HIV-negative TB patients who
were sputum smear-positive and were aged 15 years or more
(18,313 males and 7502 females), because these are the target pop-
ulations in the efficacy studies. The number of treated patients
was derived from case notification reporting from the National TB
Program [18,19] and corrected for 13% underreporting of non-Thai
patients and patients treated in the private sector [20]. Multiplying
the adjusted case notifications with one minus HIV prevalence
(24%) among TB patients [20] gives the number of HIV-negative TB
cases.
To estimate MDR-TB incidence, we multiplied the failure rate
from the initial treatment and the failure rate from the retreat-
ment with the number of patients treated.
Estimating health outcomes
The health outcomes were estimated over their lifetime in disabil-
ity-adjusted life years (DALYs), the measure introduced by the
WHO [21], rather than in quality-adjusted life years. This was done
because the calculation of DALYs has more advantages (e.g., when
comparing among interventions for many diseases) from using a
standard set of weights across all diseases while the calculation of
quality-adjusted life years does not have these advantages (it is
I) Transfer out rate (95% CI) Death rate (95% CI)
0.00 (0.00–0.00) 0.09 (0.01–0.24)
0.03 (0.00–0.11) 0.03 (0.00–0.10)
0.02 (0.01–0.04) 0.06 (0.04–0.09)
0.00 (0.00–0.00) 0.17 (0.09–0.26)
0.05 (0.03–0.07) 0.05 (0.03–0.07)
reatment; FM, family member; HW, health worker; SAT, self-admin-
ating health outcomes.
Distribution Sources Intervention
Beta [27] All interventions
4  0 Dirichlet [8] Health-worker DOT
4  1 Dirichlet [8] Community-member DOT
1, n4  7 Dirichlet [8] Family-member DOT
4  0 Dirichlet [12] Mobile phone reminder
1, n4  20 Dirichlet [8] SAT
Dirichlet [32] All interventions
92, n4  47 Dirichlet [16] All interventions
 6 Dirichlet [17] All interventions
rug resistant tuberculosis; N, total number; n1, number successfully
ber of cases transferred out; RCT, randomized controlled trial; SAT,5% C
.15)
.28)
.11)
.05)
.18)
ved testim
2, n
1, n
3  2
12, n
3  2
3  38
n3 
2, n4
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S53V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 5 0 – S 5 5based on overall health status but not for specific disease). This
study was one part of a project aimed at comparing various inter-
ventions from different diseases. Therefore, DALYs was our pre-
ferred choice.
There were two steps to calculate the DALYs for each interven-
tion. First, we estimated the health-adjusted life expectancy of each
pathway by using a life-table approach. The health-adjusted life expec-
tancy is an estimate of the average years of equivalent “full health”
ife that a person can expect to live at various ages taking into ac-
ount years lived in less than full health due to disease and/or injury
disability) [22]. Age- and sex-specific TB and background mortality
ates used to calculate health-adjusted life expectancy were derived
rom a Thai cause of death study [23]. That study undertook cause of
eath ascertainment by using verbal autopsy interviews and hospital
ecords to improve cause of death data in Thailand because the rou-
ine vital registration data has almost 40% of records with an ill-
efined cause [24–26]. The total number of deaths in Thailand was
ncreased from those recorded in the vital registration system by
orrecting for underreporting by using the 2005-2006 Survey of Pop-
lation Change [23]. The corrected cause profiles from the verbal au-
opsy interviews and medical record reviews were applied to this
stimate of total deaths by using proportionate mortality by age and
ex. The disability weight for TB, which estimates the amount of time
ost to ill health per year, was obtained from a Dutch disability
eights study [27], and the disability weight for all other causes was
erived from the Thai Burden of Disease and Injuries study [28] as the
er capita rate of prevalent years lived with disability from all causes
part from TB.
Second, we calculated an expected health-adjusted life expec-
ancy of each intervention as the sum of the health-adjusted life
xpectancy of all pathways weighted by the probability of each
athway. The difference between the expected health-adjusted
ife expectancy of each intervention and the comparator scenario
ultiplied with the number of patients treated was the health
ain of the intervention in DALYs averted. Health outcomes were
eferenced to 2005 and discounted at 3% per annum.
Table 3 – Costs of each intervention with 95% uncertainty i
Intervention Government costs (I$ million)
DOT by an HW 23 (19–29)
DOT by a CM 23 (17–31)
DOT by an FM 17 (15–19)
Mobile phone 19 (17–21)
SAT 26 (23–28)
CM, community member; DOT, directly observed treatment; FM, f
administered treatment.
Table 4 – Estimated number of MDR-TB incidence for all
interventions.
Intervention MDR-TB incidence (95% CI)
DOT by an HW 244 (6–915)
DOT by a CM 852 (300–1650)
DOT by an FM 439 (284–625)
Mobile phone 82 (2–311)
SAT 833 (638–1071)
CI, confidence interval; CM, community member; DOT, directly
observed treatment; FM, family member; HW, health worker;
MDR-TB, multi-drug resistant tuberculosis; SAT, self-adminis-
tered treatment.Estimating costs
Costs for treating those patients were estimated according to treat-
ment period and pathway. We divided costs into two categories: in-
tervention costs and medical costs. Each cost category was calcu-
lated by using the health-care perspective, incorporating costs borne
by both the government and patients. All costs were measured by
using a standardized ingredients approach, requiring information on
the quantities of all resources used and their unit costs. Total costs
were quantities of inputs multiplied with their unit costs.
Intervention costs were any costs associated with the interven-
tion. Intervention costs incurred by the government were costs
from health staff supervision and monitoring time, travel costs to
monitor patients at home, and mobile phone monitoring care. In-
tervention costs incurred by patients were travel and time costs to
be supervised or followed up.
Medical costs were the general costs for treating TB patients,
which did not differ by intervention. For instance, medical costs
incurred by the government included laboratory costs (direct
smear examination, sputum culture, drug susceptibility test),
pharmaceutical costs, and the costs of radiology and health facil-
ity. Medical costs incurred by patients and families comprised
travel and time costs to or at health facility and out-of-pocket
expenses (costs for food and drink).
All costs were reported in international dollars (I$), a hypothet-
ical currency representing the purchasing power of local currency
in a corresponding country, which is equivalent to the purchasing
power of US dollar in the United States [29]. One I$ was equal to
12.12 Thai baht for 2005 [30]. The same idea of calculating the
weighted average health-adjusted life expectancy was applied to
calculate a weighted average cost. Future costs were discounted to
2005 values by using a 3% discount rate. Details of all costs are
described in Supplemental Material found at doi:10.1016/j.jval.
2011.11.006.
Cost-effectiveness analysis
An incremental cost-effectiveness ratio (ICER) was evaluated for
each intervention. The ICER was calculated by dividing the incre-
mental cost (intervention cost minus comparator cost) by the
DALYs averted. We adopted cost-effectiveness thresholds from
the CHOosing Interventions that are Cost Effective project [31].
These thresholds are 1) highly cost-effective when the ICER is less
than one time the gross domestic product per capita per DALY and
2) cost-effective when the ICER is less than three times the gross
domestic product per capita per DALY. Ninety-five percent uncer-
tainty intervals were determined for all outcome measures by us-
ing Monte Carlo simulation with 2000 iterations in Ersatz
(www.epigear.com). Uncertainty distributions surrounding pa-
rameters for estimating health outcomes are provided in Table 2.
We used beta distribution for disability weight (value between 0
and 1). The beta distribution requires two parameters: alpha1 and
alpha2. These parameters can be derived from sample mean and
variance by using the method of moments. A Dirichlet distribution
vals for 25,815 treated patients.
Patient costs (I$ million) Total costs (I$ million)
19 (16–23) 42 (36–50)
3 (2–5) 26 (19–35)
3 (2–3) 20 (18–22)
1 (1–2) 20 (18–23)
3 (3–4) 29 (26–32)
member; HW, health worker; I$, international dollars; SAT, self-nter
amilyis used for numbers of treatment outcomes that have more than
t
m
f
1
i
M
t
a
T
o
(
(
a
c
t
S
m
b
lf-ad
S54 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 5 0 – S 5 5two outcomes. This distribution is the multivariate generalization
of the beta distribution for multinomial data, which can be used to
represent the proportions of those treatment outcomes.
All input parameters for estimating costs were not obtained from
a sample observation but from a population observation or a report
or an expert’s opinion, and therefore there was no sampling uncer-
tainty. We used a Pert distribution to model uncertainty around all
cost parameters. The Pert distribution is a rescaled and reparam-
etrized beta distribution [33] that requires three parameters: mini-
mum, mode, and maximum values. The maximum and minimum
values for the government cost and the patient cost were assumed to
be10% and25% of the mode values, respectively.
Results
Table 3 shows government, patient, and total costs of each interven-
ion. SAT was the most expensive intervention to the government,
ore expensive than health-worker DOT. This was due to the higher
ailure rate of SAT compared with that of health-worker DOT (Table
). The high failure rate of SAT resulted in a high estimate of MDR-TB
ncidence (Table 4). And consequently, there were greater costs for
DR-TB treatment. Health-worker DOT was the most expensive in-
ervention from the patient perspective. It involved substantial travel
nd time costs to be supervised at the health center.
Cost-effectiveness results did not clearly indicate a preference for
any of the interventions analyzed. The median ICER for health-
worker DOT, community-member DOT, and family-member DOT
was I$1100 per DALY, dominant (less costly, more DALYs averted),
and dominant, respectively. Although the median ICERs for DOT in-
terventions were favorable with the median ICER below the thresh-
old of one time gross domestic product per capita per DALY or I$9000
per DALY, the uncertainty ranges around the health gain in DALYs
were wide and crossed zero (Table 5 and Fig. 2), indicating that no
distinction could be made in cost-effectiveness between any of the
DOT options and SAT. There were cost savings (from less retreat-
ment or MDR-TB treatment) associated with family-member DOT at
–I$9 million (95% uncertainty interval I$12 million to –I$5 million)
(Fig. 2) because the trial treatment failure rate was significantly lower
than that for SAT.
Although the mobile phone intervention was cheaper than
SAT (Table 5), this intervention led to less health gain. As can be
seen in Figure 2, mobile phone reminder predominantly fell in the
southwest quadrant of the cost-effectiveness plane, indicating a
cost-saving for less health gain.
Discussion
Effects of the interventions in this study had wide overlapping
confidence intervals because results were derived from small
studies. Therefore, we could not state which intervention was the
most cost-effective. The median ICERs of our DOT interventions
Table 5 – Cost-effectiveness of TB control interventions wi
Intervention Incremental costs
(I$ million)
DOT by an HW 13 (7–22) 7
DOT by a CM 3 (11 to 7) 13
DOT by an FM 9 (12 to 5) 9
Mobile phone 9 (12 to 5) 26
All results are shown rounded to two significant digits.
CM, community member; DALYs, disability-adjusted life years; DOT, d
incremental cost-effectiveness ratio; I$, international dollars; SAT, sewere as favorable as the results from a study in Brazil [6], with amedian ICER of $86 per DALY averted (less than the $2710-per-
DALY threshold) for DOT (unknown observer type) compared with
SAT. However, the Brazilian study showed narrower uncertainty
ranges around the health benefits than did the current study. This
may be due to its use of efficacy from a larger cohort. Although the
exact size of the cohort of the Brazilian study was not stated, it can
be presumed that it was much larger than the cohort of our study
because the Brazilian study was based on programmatic outcomes
from all cases recorded by the Health Department in Rio de Ja-
neiro. We adopted intervention effects from a small (836 partici-
pants) randomized controlled trial, which had wide 95% confi-
dence intervals and overlap between different interventions.
A study from Pakistan [5] found that DOT interventions were
not favorable because SAT was the lowest cost intervention ($164
per case cured). This may be because the time horizon for the
study in Pakistan was 8 months, which included only the cost for
initial treatment but not the treatment costs associated with treat-
ment failure and drug resistance. This may have contributed to a
lower cost for SAT despite it having the highest default rate [34].
he results from the Pakistan study could not be compared with
ur results as there was difference in outcome measurement
DALYs averted vs. cases cured). We took all treatment outcomes
cured, treatment completed, treatment failure, died, defaulted,
nd transferred out) of each intervention into account when cal-
ulating the health outcome through a patient’s lifetime, whereas
he study from Pakistan focused only on cases cured.
Although the mobile phone intervention was cheaper than
AT, the health gain was much less (Table 5). This was due to the
ortality rate in the small trial (70 patients) of this intervention
eing much higher than for each of the other treatment strategies.
% uncertainty intervals when compared with SAT.
Ys averted Median ICER (I$/DALY)
50,000 to 43,000) 1,100 (270 to dominated)
21,000 to 37,000) Dominant (dominant to dominated)
7,200 to 25,000) Dominant (dominant to 1,300)
68,000 to 11,000) 350 (dominant to 120)
ly observed treatment; FM, family member; HW, health worker; ICER,
ministered treatment.
Fig. 2 – Cost-effectiveness of the TB control interventions when
compared with SAT. CM, directly observed treatment by a
community member; DALY, disability-adjusted life years; FM,
directly observed treatment by a family member; HW, directly
observed treatment by a health worker; I$, international dollar;th 95
DAL
,900 (
,000 (
,400 (
,000 (
irectSAT, self-administered treatment.
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S55V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 5 0 – S 5 5Authors of the pilot study, however, stated that the high mortality
rate was likely to have been due to the selection of an elderly
population and comorbidities in this population rather than a re-
sult of the intervention. A bigger study with a control group and
representative age distribution is needed to say more definitively
what the merits of the mobile phone intervention are.
A key limitation of this study is the relatively weak evidence. Even
though treatment outcomes of DOT interventions and SAT were ob-
tained from a Thai randomized controlled trial, it was only a rather
small trial. Moreover, an international meta-analysis as part of a Co-
chrane review [7] found no evidence that DOT interventions showed
ure rates better than SAT. Nevertheless, some have argued that nei-
her the Cochrane review nor the other research considers the main
urpose of DOT, which is to prevent the development of resistance to
ifampicin [35]. Our study considers all treatment outcomes rather
han only cure rate to estimate cost and health outcomes from initial
reatment through MDR-TB treatment.
In conclusion, because of the large uncertainty intervals
round health gain for DOT strategies, it remains inconclusive
hether DOT strategies are more cost-effective than SAT. It is
vident, however, that family-member DOT costs are less than
hose for the alternative strategies.
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